{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:01:40Z","timestamp":1784541700076,"version":"3.55.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["grant no. ZK2022665"],"award-info":[{"award-number":["grant no. ZK2022665"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06620-w","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:55:13Z","timestamp":1784534113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor microenvironment-mediated hematologic toxicity of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer: mechanisms, risk stratification, and clinical management"],"prefix":"10.1007","volume":"44","author":[{"given":"Ziye","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"2","key":"6620_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160. https:\/\/doi.org\/10.1016\/S1470-2045(14)71205-7","journal-title":"Lancet Oncol"},{"issue":"13","key":"6620_CR2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"issue":"15","key":"6620_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502\u20131512. https:\/\/doi.org\/10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"issue":"10459","key":"6620_CR4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K et al (2024) 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404(10459):1227\u20131239. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2","journal-title":"Lancet"},{"key":"6620_CR5","doi-asserted-by":"publisher","first-page":"1060922","DOI":"10.3389\/fmed.2022.1060922","volume":"9","author":"O Sartor","year":"2022","unstructured":"Sartor O, Baghian A (2022) Prostate specific membrane antigen binding radiopharmaceuticals: current data and new concepts. Front Med (Lausanne) 9:1060922","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"6620_CR6","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL et al (2016) 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med 57(12):1941\u20131944","journal-title":"J Nucl Med"},{"issue":"8","key":"6620_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/ph18081215","volume":"18","author":"W Jalloul","year":"2025","unstructured":"Jalloul W, Ghizdovat V, Saviuc A, Jalloul D, Grierosu IC, Stefanescu C (2025) Targeted alpha therapy: exploring the clinical insights into [225Ac]Ac-PSMA and its relevance compared with [177Lu]Lu-PSMA in advanced prostate cancer management. Pharmaceuticals (Basel) 18(8):1215","journal-title":"Pharmaceuticals (Basel)"},{"issue":"20","key":"6620_CR8","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.7150\/thno.48107","volume":"10","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C (2020) Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics 10(20):9364\u20139377","journal-title":"Theranostics"},{"issue":"12","key":"6620_CR9","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1007\/s00259-023-06340-y","volume":"50","author":"S Ballal","year":"2023","unstructured":"Ballal S, Yadav MP, Satapathy S et al (2023) Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging 50(12):3777\u20133789","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"6620_CR10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H et al (2017) Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med 58(10):1624\u20131631","journal-title":"J Nucl Med"},{"issue":"5","key":"6620_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherl","year":"2021","unstructured":"Zacherl MJ, Gildehaus FJ, Mittlmeier L et al (2021) First clinical results for PSMA-targeted \u03b1-therapy using (225)Ac-PSMA-I&T in advanced-mCRPC patients. J Nucl Med 62(5):669\u2013674","journal-title":"J Nucl Med"},{"key":"6620_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.796657","volume":"12","author":"J Ma","year":"2022","unstructured":"Ma J, Li L, Liao T, Gong W, Zhang C (2022) Efficacy and safety of (225)Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Front Oncol 12:796657","journal-title":"Front Oncol"},{"issue":"9","key":"6620_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/pros.24137","volume":"81","author":"S Ballal","year":"2021","unstructured":"Ballal S, Yadav MP, Sahoo RK, Tripathi M, Dwivedi SN, Bal C (2021) (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate 81(9):580\u2013591","journal-title":"Prostate"},{"issue":"6","key":"6620_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/pros.24857","volume":"85","author":"H Besiroglu","year":"2025","unstructured":"Besiroglu H, Kadihasanoglu M (2025) The safety and efficacy of targeted alpha therapy, Ac-225 prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate 85(6):541\u2013557","journal-title":"Prostate"},{"issue":"10","key":"6620_CR15","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","volume":"49","author":"IO Lawal","year":"2022","unstructured":"Lawal IO, Morgenstern A, Vorster M et al (2022) Hematologic toxicity profile and efficacy of [(225)Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 49(10):3581\u20133592","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6620_CR16","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ad7b9a","author":"CC Oliveira-Silva","year":"2024","unstructured":"Oliveira-Silva CC, Maillard MS, Silva R, S\u00e1 LV (2024) Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer. Phys Med Biol. https:\/\/doi.org\/10.1088\/1361-6560\/ad7b9a","journal-title":"Phys Med Biol"},{"issue":"2","key":"6620_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C et al (2024) Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol 25(2):175\u2013183","journal-title":"Lancet Oncol"},{"issue":"8","key":"6620_CR18","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.7150\/thno.106574","volume":"15","author":"G Ninatti","year":"2025","unstructured":"Ninatti G, Scilipoti P, Pini C et al (2025) Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis. Theranostics 15(8):3386\u20133399","journal-title":"Theranostics"},{"issue":"3","key":"6620_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/cancers17030405","volume":"17","author":"E Perrone","year":"2025","unstructured":"Perrone E, Giordano A, Calcagni ML et al (2025) Long-term safety and survival outcomes of [(225)Ac]Ac-PSMA (prostate-specific membrane antigen) and [(225)Ac]Ac-\/[(177)Lu]Lu-PSMA (TANDEM) radioligand therapy (PRLT) in metastatic castration-resistant prostate cancer. Cancers (Basel) 17(3):405","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6620_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-022-00891-1","volume":"12","author":"F Kind","year":"2022","unstructured":"Kind F, Michalski K, Yousefzadeh-Nowshahr E, Meyer PT, Mix M, Ruf J (2022) Bone marrow impairment during early [(177)Lu]PSMA-617 radioligand therapy: haematotoxicity or tumour progression. EJNMMI Res 12(1):20","journal-title":"EJNMMI Res"},{"issue":"4","key":"6620_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/MOU.0000000000001300","volume":"35","author":"D Ventura","year":"2025","unstructured":"Ventura D, Noto B, Jauregui NR, Roll W, Rahbar K (2025) Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis. Curr Opin Urol 35(4):472\u2013480","journal-title":"Curr Opin Urol"},{"issue":"4","key":"6620_CR22","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1097\/RLU.0000000000005640","volume":"50","author":"F Rosar","year":"2025","unstructured":"Rosar F, Khreish F, Nagel LS et al (2025) 225 Ac-PSMA-617 augmentation after insufficient response under 177 Lu-PSMA-617 radioligand therapy in mCRPC: evaluation of outcome and safety from a prospective registry (REALITY study). Clin Nucl Med 50(4):e202\u2013e206","journal-title":"Clin Nucl Med"},{"key":"6620_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07632-1","author":"L Widjaja","year":"2025","unstructured":"Widjaja L, Hornfeck J, Siegmund SC et al (2025) Refining the clinical utility of [(177)Lu]Lu\/[(225)Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-025-07632-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6620_CR24","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ijrobp.2023.06.003","volume":"117","author":"I Liatsou","year":"2023","unstructured":"Liatsou I, Josefsson A, Yu J et al (2023) Early normal tissue effects and bone marrow relative biological effectiveness for an actinium 225-labeled HER2\/neu-targeting antibody. Int J Radiat Oncol Biol Phys 117(4):1028\u20131037","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"6620_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA et al (2021) A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol 80(1):82\u201394","journal-title":"Eur Urol"},{"issue":"1","key":"6620_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","volume":"11","author":"D Groener","year":"2021","unstructured":"Groener D, Nguyen CT, Baumgarten J et al (2021) Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res 11(1):61","journal-title":"EJNMMI Res"},{"issue":"4","key":"6620_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","volume":"85","author":"KN Chi","year":"2024","unstructured":"Chi KN, Armstrong AJ, Krause BJ et al (2024) Safety analyses of the phase 3 VISION trial of [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur Urol 85(4):382\u2013391","journal-title":"Eur Urol"},{"issue":"2","key":"6620_CR28","first-page":"149","volume":"28","author":"H Liu","year":"2025","unstructured":"Liu H, Jiao M, Wang J, Zhang C (2025) The efficacy and safety of (225)Ac-PSMA RLT targeted therapy for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Hell J Nucl Med 28(2):149\u2013167","journal-title":"Hell J Nucl Med"},{"issue":"17","key":"6620_CR29","doi-asserted-by":"publisher","first-page":"12935","DOI":"10.1074\/jbc.M109.071696","volume":"285","author":"SH Moon","year":"2010","unstructured":"Moon SH, Lin L, Zhang X et al (2010) Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair. J Biol Chem 285(17):12935\u201312947","journal-title":"J Biol Chem"},{"issue":"4","key":"6620_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MOH.0000000000000715","volume":"29","author":"S Barajas","year":"2022","unstructured":"Barajas S, Cai W, Liu Y (2022) Role of p53 in regulation of hematopoiesis in health and disease. Curr Opin Hematol 29(4):194\u2013200","journal-title":"Curr Opin Hematol"},{"issue":"18","key":"6620_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186602","volume":"21","author":"SJ Roobol","year":"2020","unstructured":"Roobol SJ, van den Bent I, van Cappellen WA et al (2020) Comparison of high- and low-LET radiation-induced DNA double-strand break processing in living cells. Int J Mol Sci 21(18):6602","journal-title":"Int J Mol Sci"},{"key":"6620_CR32","doi-asserted-by":"publisher","first-page":"1569143","DOI":"10.3389\/fmed.2025.1569143","volume":"12","author":"Z Wang","year":"2025","unstructured":"Wang Z, Tang W, Liu M et al (2025) Actinium-225-PSMA-617 treatment in a patient with advanced prostate cancer causes secondary myelofibrosis: a case report and literature review. Front Med (Lausanne) 12:1569143","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"6620_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41181-025-00333-y","volume":"10","author":"MM Vilangattil","year":"2025","unstructured":"Vilangattil MM, Swaidan A, Godinez J et al (2025) Hematological toxicity of [(225)Ac]Ac-PSMA-617 and [(177)Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model. EJNMMI Radiopharm Chem 10(1):12","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"10","key":"6620_CR34","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/pros.24531","volume":"83","author":"J Stangl-Kremser","year":"2023","unstructured":"Stangl-Kremser J, Ricaurte-Fajardo A, Subramanian K et al (2023) Response to RL-225Ac in prostate cancer: effect of prior treatment with RL-177Lu: a systematic review of the literature. Prostate 83(10):901\u2013911","journal-title":"Prostate"},{"key":"6620_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1023177","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang B, Lang X, Li X (2022) The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol 12:1023177","journal-title":"Front Oncol"},{"key":"6620_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/biom12050635","author":"P Mallikarjuna","year":"2022","unstructured":"Mallikarjuna P, Zhou Y, Landstr\u00f6m M (2022) The synergistic cooperation between TGF-\u03b2 and hypoxia in cancer and fibrosis. Biomolecules. https:\/\/doi.org\/10.3390\/biom12050635","journal-title":"Biomolecules"},{"issue":"7","key":"6620_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8070062","volume":"8","author":"M Mazon","year":"2016","unstructured":"Mazon M, Masi D, Carreau M (2016) Modulating Dickkopf-1: a strategy to monitor or treat cancer. Cancers (Basel) 8(7):62","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6620_CR38","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/bjh.19049","volume":"203","author":"K Mizuhara","year":"2023","unstructured":"Mizuhara K, Shimura Y, Tsukamoto T et al (2023) Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma. Br J Haematol 203(3):426\u2013438","journal-title":"Br J Haematol"},{"issue":"7578","key":"6620_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino A, Costa-Silva B, Shen TL et al (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329\u2013335","journal-title":"Nature"},{"issue":"4","key":"6620_CR40","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/ijms22041881","volume":"22","author":"T Yamaguchi","year":"2021","unstructured":"Yamaguchi T, Kawamoto E, Gaowa A, Park EJ, Shimaoka M (2021) Remodeling of bone marrow niches and roles of exosomes in leukemia. Int J Mol Sci 22(4):1881","journal-title":"Int J Mol Sci"},{"key":"6620_CR41","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S570831","author":"A Luhung","year":"2026","unstructured":"Luhung A, Hasanah AN, Ramdhani D (2026) Radiopharmaceutical: an update and comparison of preclinical investigation result of alpha and beta emitter radioisotope. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S570831","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"6620_CR42","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2005-04-1418","volume":"107","author":"Y Wang","year":"2006","unstructured":"Wang Y, Schulte BA, LaRue AC et al (2006) Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 107(1):358\u2013366. https:\/\/doi.org\/10.1182\/blood-2005-04-1418","journal-title":"Blood"},{"issue":"1","key":"6620_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13287-024-03853-7","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen X, Wang X et al (2024) Insights into ionizing radiation-induced bone marrow hematopoietic stem cell injury. Stem Cell Res Ther 15(1):222. https:\/\/doi.org\/10.1186\/s13287-024-03853-7","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"6620_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K et al (2021) Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol 79(3):343\u2013350","journal-title":"Eur Urol"},{"issue":"3","key":"6620_CR45","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCRESAHA.117.312115","volume":"122","author":"JJ Fuster","year":"2018","unstructured":"Fuster JJ, Walsh K (2018) Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. Circ Res 122(3):523\u2013532","journal-title":"Circ Res"},{"issue":"1","key":"6620_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22053-y","volume":"12","author":"T Fujino","year":"2021","unstructured":"Fujino T, Goyama S, Sugiura Y et al (2021) Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt\/mTOR pathway. Nat Commun 12(1):1826","journal-title":"Nat Commun"},{"issue":"3","key":"6620_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/2643-3230.BCD-21-0132","volume":"3","author":"CR Zhang","year":"2022","unstructured":"Zhang CR, Ostrander EL, Kukhar O et al (2022) Txnip enhances fitness of Dnmt3a-mutant hematopoietic stem cells via p21. Blood Cancer Discov 3(3):220\u2013239","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"6620_CR48","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","volume":"87","author":"YH Dai","year":"2025","unstructured":"Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA (2025) A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer. Eur Urol 87(4):398\u2013408","journal-title":"Eur Urol"},{"issue":"9","key":"6620_CR49","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.7150\/thno.109860","volume":"15","author":"N Poterszman","year":"2025","unstructured":"Poterszman N, Hammer-Lefevre C, Porot C, Salvadori J, Barth\u00e9l\u00e9my P, Somme F (2025) Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [(177)Lu]Lu\u2013PSMA\u2013617 therapy in metastatic castration-resistant prostate cancer. Theranostics 15(9):3724\u20133732","journal-title":"Theranostics"},{"issue":"1","key":"6620_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41391-021-00424-2","volume":"25","author":"BM Priv\u00e9","year":"2022","unstructured":"Priv\u00e9 BM, Slootbeek P, Laarhuis BI et al (2022) Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 25(1):71\u201378","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"6620_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-022-00891-1","volume":"12","author":"F Kind","year":"2022","unstructured":"Kind F, Michalski K, Yousefzadeh-Nowshahr E, Meyer PT, Mix M, Ruf J (2022) Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: haematotoxicity or tumour progression. EJNMMI Res 12(1):20","journal-title":"EJNMMI Res"},{"issue":"3","key":"6620_CR52","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00259-025-07541-3","volume":"53","author":"N Borges","year":"2026","unstructured":"Borges N, Losee M, Liu M et al (2026) Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET\/CT imaging. Eur J Nucl Med Mol Imaging 53(3):1559\u20131569","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6620_CR53","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2967\/jnumed.124.268640","volume":"66","author":"M Eifer","year":"2025","unstructured":"Eifer M, Sutherland D, Goncalves I et al (2025) Therapy-related myeloid neoplasms after [(177)Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a case series. J Nucl Med 66(4):579\u2013584","journal-title":"J Nucl Med"},{"issue":"4","key":"6620_CR54","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00259-024-07006-z","volume":"52","author":"MB Bastian","year":"2025","unstructured":"Bastian MB, Sieben M, Blickle A et al (2025) Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia. Eur J Nucl Med Mol Imaging 52(4):1271\u20131277","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"6620_CR55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/RLU.0000000000005968","volume":"50","author":"MB Bastian","year":"2025","unstructured":"Bastian MB, W\u00f6rl B, Blickle A et al (2025) PSMA radioligand therapy in advanced age: insights from an 85y+ mCRPC patient cohort. Clin Nucl Med 50(9):825\u2013829","journal-title":"Clin Nucl Med"},{"issue":"13","key":"6620_CR56","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1007\/s00259-025-07346-4","volume":"52","author":"MB Bastian","year":"2025","unstructured":"Bastian MB, W\u00f6rl B, Blickle A et al (2025) Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3). Eur J Nucl Med Mol Imaging 52(13):4893\u20134901","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"45","key":"6620_CR57","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.1038\/s41388-020-01479-6","volume":"39","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Dalrymple SL, Coleman I et al (2020) Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene 39(45):6935\u20136949","journal-title":"Oncogene"},{"key":"6620_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030405","author":"E Perrone","year":"2025","unstructured":"Perrone E, Giordano A, Calcagni ML et al (2025) Long-term safety and survival outcomes of [225Ac]Ac-PSMA (prostate-specific membrane antigen) and [225Ac]Ac-\/[177Lu]Lu-PSMA (TANDEM) radioligand therapy (PRLT) in metastatic castration-resistant prostate cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17030405","journal-title":"Cancers (Basel)"},{"issue":"10","key":"6620_CR59","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.21037\/tau-20-1135","volume":"10","author":"L Lunger","year":"2021","unstructured":"Lunger L, Tauber R, Feuerecker B, Gschwend JE, Eiber M, Heck MM (2021) Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer. Transl Androl Urol 10(10):3963\u20133971","journal-title":"Transl Androl Urol"},{"issue":"3","key":"6620_CR60","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","volume":"24","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Sood A, Das CK, Mittal BR (2021) Evolving role of (225)Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 24(3):880\u2013890","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"6620_CR61","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/14737140.2023.2247562","volume":"23","author":"RV Parghane","year":"2023","unstructured":"Parghane RV, Basu S (2023) PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects. Expert Rev Anticancer Ther 23(9):959\u2013975","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"6620_CR62","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","volume":"28","author":"B Ramnaraign","year":"2023","unstructured":"Ramnaraign B, Sartor O (2023) PSMA-targeted radiopharmaceuticals in prostate cancer: current data and new trials. Oncologist 28(5):392\u2013401","journal-title":"Oncologist"},{"issue":"10","key":"6620_CR63","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","volume":"49","author":"IO Lawal","year":"2022","unstructured":"Lawal IO, Morgenstern A, Vorster M et al (2022) Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 49(10):3581\u20133592","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6620_CR64","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2967\/jnumed.124.268640","volume":"66","author":"M Eifer","year":"2025","unstructured":"Eifer M, Sutherland D, Goncalves I et al (2025) Therapy-related myeloid neoplasms after [177Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a case series. J Nucl Med 66(4):579\u2013584","journal-title":"J Nucl Med"},{"issue":"9","key":"6620_CR65","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.7150\/thno.109860","volume":"15","author":"N Poterszman","year":"2025","unstructured":"Poterszman N, Hammer-Lefevre C, Porot C, Salvadori J, Barth\u00e9l\u00e9my P, Somme F (2025) Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [177Lu]Lu\u2011PSMA\u2011617 therapy in metastatic castration-resistant prostate cancer. Theranostics 15(9):3724\u20133732","journal-title":"Theranostics"},{"issue":"7","key":"6620_CR66","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/RLU.0000000000005253","volume":"49","author":"F Rosar","year":"2024","unstructured":"Rosar F, Burgard C, Rohloff LV et al (2024) 225 Ac-PSMA-617 augmentation in high-risk mCRPC undergoing 177 Lu-PSMA-617 radioligand therapy: pilot experience from a prospective registry. Clin Nucl Med 49(7):621\u2013629","journal-title":"Clin Nucl Med"},{"issue":"9","key":"6620_CR67","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19(9):589\u2013608","journal-title":"Nat Rev Drug Discov"},{"key":"6620_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2025.104966","volume":"133","author":"S Tronchin","year":"2025","unstructured":"Tronchin S, Forster J, Hickson K, Bezak E (2025) Small-scale bone marrow dosimetry study for 225Ac. Phys Med 133:104966","journal-title":"Phys Med"},{"issue":"7","key":"6620_CR69","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1007\/s00259-023-06179-3","volume":"50","author":"G Treglia","year":"2023","unstructured":"Treglia G, Albano D (2023) FAPI PET\/CT in infectious, inflammatory, and rheumatological diseases: watch it like a hawk or one swallow does not make a summer. Eur J Nucl Med Mol Imaging 50(7):1848\u20131850","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6620_CR70","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00259-025-07632-1","volume":"53","author":"L Widjaja","year":"2026","unstructured":"Widjaja L, Hornfeck J, Siegmund SC et al (2026) Refining the clinical utility of [(177)Lu]Lu\/[(225)Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging 53(4):2271\u20132281","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6620_CR71","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","volume":"49","author":"DA Pattison","year":"2022","unstructured":"Pattison DA, Debowski M, Gulhane B et al (2022) Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging 49(2):763\u2013776","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"6620_CR72","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1515\/cclm-2020-0083","volume":"58","author":"C Fiala","year":"2020","unstructured":"Fiala C, Diamandis EP (2020) Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection. Clin Chem Lab Med 58(10):1651\u20131653","journal-title":"Clin Chem Lab Med"},{"issue":"43","key":"6620_CR73","doi-asserted-by":"publisher","first-page":"7210","DOI":"10.1038\/sj.onc.1207941","volume":"23","author":"L Coulombel","year":"2004","unstructured":"Coulombel L (2004) Identification of hematopoietic stem\/progenitor cells: strength and drawbacks of functional assays. Oncogene 23(43):7210\u20137222","journal-title":"Oncogene"},{"issue":"1","key":"6620_CR74","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s41181-025-00344-9","volume":"10","author":"M Aurilio","year":"2025","unstructured":"Aurilio M, Esposito A, Buonanno M et al (2025) [225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production. EJNMMI Radiopharm Chem 10(1):20. https:\/\/doi.org\/10.1186\/s41181-025-00344-9","journal-title":"EJNMMI Radiopharm Chem"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06620-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06620-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06620-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:02:39Z","timestamp":1784538159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06620-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6620"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06620-w","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article does not contain individual person\u2019s data in any form.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"506"}}